• New Therapies for Metastatic Castrate-Resistant Prostate Cancer: Radioligand Therapy and PSMA Biomarker-Based Imaging

  • Sep 21 2023
  • Length: 22 mins
  • Podcast

New Therapies for Metastatic Castrate-Resistant Prostate Cancer: Radioligand Therapy and PSMA Biomarker-Based Imaging

  • Summary

  • Drs Sandhya Srinivas and Oliver Sartor discuss the VISION study, new therapies for patients with metastatic castrate-resistant prostate cancer, and PSMA biomarker-based imaging.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988736). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

    Resources

    Lutetium-177-PSMA-617 for Metastatic Castration-resistant Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/34161051/

    Prostate Cancer Theranostics: PSMA Targeted Therapy https://pubmed.ncbi.nlm.nih.gov/34053583/

    Piflufolastat F-18 (18F-DCFPyL) for PSMA PET Imaging in Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/35603510/

    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in Prostate Cancer https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

    German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients https://pubmed.ncbi.nlm.nih.gov/27765862/

    Results of a Prospective Phase 2 Pilot Trial of 177Lu-PSMA-617 Therapy for Metastatic Castration-resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression https://pubmed.ncbi.nlm.nih.gov/30425003/

    Effect of Radium-223 Dichloride on Symptomatic Skeletal Events in Patients With Castration-resistant Prostate Cancer and Bone Metastases: Results From a Phase 3, Double-blind, Randomised Trial https://pubmed.ncbi.nlm.nih.gov/24836273/

    Long-term Follow-up and Outcomes of Retreatment in an Expanded 50-patient Single-center Phase II Prospective Trial of 177Lu-PSMA-617 Theranostics in Metastatic Castration-resistant Prostate Cancer https://pubmed.ncbi.nlm.nih.gov/31732676/

    [177Lu]Lu-PSMA-617 Versus Cabazitaxel in Patients With Metastatic Castration-resistant Prostate Cancer (TheraP): A Randomised, Open-label, Phase 2 Trial https://pubmed.ncbi.nlm.nih.gov/33581798/

    Prednisone Plus Cabazitaxel or Mitoxantrone for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel Treatment: A Randomised Open-label Trial https://pubmed.ncbi.nlm.nih.gov/20888992/

    [177Lu]Lu-PSMA-617 in PSMA-positive Metastatic Castration-resistant Prostate Cancer: Prior and Concomitant Treatment Subgroup Analyses of the VISION Trial https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.5001

    PSMAfore: A Phase 3 Study to Compare 177Lu-PSMA-617 Treatment With a Change in Androgen Receptor Pathway Inhibitor in Taxane-naïve Patients With Metastatic Castration-resistant Prostate Cancer https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.6_suppl.TPS211

    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about New Therapies for Metastatic Castrate-Resistant Prostate Cancer: Radioligand Therapy and PSMA Biomarker-Based Imaging

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.